迪安诊断9月9日获融资买入3595.53万元，融资余额6.82亿元

Core Insights - On September 9, 2023, Dian Diagnostics experienced a decline of 2.92% in stock price, with a trading volume of 409 million yuan [1] - The company reported a net financing outflow of 13.31 million yuan on the same day, with a total financing and securities balance of 684 million yuan [1][2] - For the first half of 2025, Dian Diagnostics achieved a revenue of 4.936 billion yuan, a year-on-year decrease of 20.61%, and a net profit of 10.277 million yuan, down 85.68% year-on-year [2] Financing and Securities - On September 9, 2023, Dian Diagnostics had a financing buy-in of 35.955 million yuan, with a current financing balance of 6.82 billion yuan, representing 6.31% of its market capitalization [1] - The financing balance is above the 90th percentile of the past year, indicating a high level of financing activity [1] - The company had a securities lending balance of 2.0534 million yuan, with a lending volume of 118,900 shares on the same day [1] Shareholder Structure - As of June 30, 2025, the number of shareholders for Dian Diagnostics was 48,300, a decrease of 11.32% from the previous period [2] - The average number of circulating shares per person increased by 12.77% to 10,376 shares [2] - Major shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 3.4713 million shares, and a new shareholder,招商优势企业混合A, holding 11 million shares [3]